The future of chemotherapy in malignant brain tumors.
Malignant brain tumors respond poorly to chemotherapy. This therapeutic resistance is the result of the marked heterogeneity of malignant gliomas in vivo and in vitro. Different factors, as specific markers, DNA distribution curves, morphology, chromosomal constitution, invasiveness and growth characteristics are considered for the understanding of the biology of malignant brain tumors. A better knowledge of this biology should provide new chemotherapeutic strategies.
D000970:Antineoplastic Agents / Q000097:blood / Q000627:therapeutic use*; D001812:Blood-Brain Barrier / Q000187:drug effects; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D004273:DNA, Neoplasm / Q000378:metabolism; D005544:Forecasting; D005904:Glial Fibrillary Acidic Protein / Q000097:blood; D006801:Humans; D007527:Isoenzymes / Q000097:blood; D007700:Kinetics; D011379:Prognosis; D014410:Tumor Stem Cell Assay
D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D005904:Glial Fibrillary Acidic Protein; D007527:Isoenzymes